AN ACT

To amend and reenact R.S. 22:1028.3(B)(2) relative to the medical necessity for genetic testing of certain cancer mutations; to require medical necessity for genetic testing of certain cancer mutations is based on nationally recognized clinical practice guidelines; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 22:1028.3(B)(2) is hereby amended and reenacted to read as follows:

§1028.3. Required coverage for genetic testing for cancer

B.(1) *          *          *

(2) The coverage provided in this Section may be subject to annual deductibles, coinsurance, and copayment provisions as are consistent with those established under the health coverage plan. The coverage provided under this Section may be subject to applicable evidence-based medical necessity criteria that shall be based on nationally recognized clinical practice guidelines from institutions like the National Comprehensive Cancer Network, the American Cancer Society, and the Food and Drug Administration labeling under the plan.

*          *          *

Coding: Words which are struck through are deletions from existing law; words in boldface type and underscored are additions.
Section 2. This Act shall become effective on July 1, 2022.

The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Beth O’Quin.

DIGEST

Present law provides coverage can be subject to annual deductibles, coinsurance, copayment provisions established under a health coverage plan and coverage for genetic testing of certain cancer mutations can be subject to applicable evidence-based medical necessity criteria under a health plan.

Proposed law removes provision that genetic testing of certain cancer mutations can be subject to evidence-based medical necessity criteria under a health plan but requires medical necessity for genetic testing of certain cancer mutations based on nationally recognized clinical practice guidelines from institutions like the National Comprehensive Cancer Network, the American Cancer Society, and the Food and Drug Administration labeling.

Effective on July 1, 2022.

(Amends R.S. 22:1028.3(B)(2))